Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Retained Earnings (2016 - 2025)

Lexaria Bioscience's Retained Earnings history spans 11 years, with the latest figure at -$65.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 19.89% year-over-year to -$65.1 million; the TTM value through Nov 2025 reached -$65.1 million, down 19.89%, while the annual FY2025 figure was -$70335.0, 254.94% down from the prior year.
  • Retained Earnings for Q4 2025 was -$65.1 million at Lexaria Bioscience, down from -$70335.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at -$19816.0 in Q3 2024 and bottomed at -$65.1 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$36.4 million (2022), against an average of -$31.1 million.
  • The largest annual shift saw Retained Earnings soared 99.95% in 2024 before it tumbled 277796.16% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$33.8 million in 2021, then dropped by 20.79% to -$40.9 million in 2022, then decreased by 14.9% to -$46.9 million in 2023, then dropped by 15.59% to -$54.3 million in 2024, then dropped by 19.89% to -$65.1 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Retained Earnings are -$65.1 million (Q4 2025), -$70335.0 (Q3 2025), and -$60.8 million (Q2 2025).